Cyprus/Greece/MaltaCyprusGreeceMalta

Research reform

10.12.2011

Athens – Greek researchers have called on members of the international research community to sensitise their governments to the problems in their country’s research landscape. “The orderly execution of the badly needed reforms takes time,” Michalis Haliassos and others said in a open letter. Haliassos is a professor of economics at the University of Frankfurt. Restructuring quickly would be only possible with arbitrary cuts, the researchers added, and could harm the research community in Greece permanently.
“No one doubts comprehensive reforms are necessary in Greece’s research infrastructure,” Haliassos said, but qualified that by saying indiscriminately laying off staff or closing research centres would hamper the long-term recovery of the country’s economy: “International creditors must keep up the pressure for reforms, but they shouldn’t be too impatient regarding the time frame,” he said. “We need to heal the patient – not kill him with an overdose.”
In an op-ed article a few days earlier, Kevin Featherstone – an economist and the first foreign member of the Greek National Council for Research and Technology – said the council is “busy putting in place reforms that will radically alter the research landscape (and)…it is imperative that Greece be afforded the opportunity for an orderly implementation of such measures."

Cyprus/Greece/MaltaCyprusGreeceMalta

06.03.2005

Athens - A three-day conference covering all issues of biotechnology at both fundamental and application level will be held in July this year in Athens: “2nd International Greek Biotechnology Forum - IGBF2”. The event aims at...

Cyprus/Greece/MaltaCyprusGreeceMalta

05.02.2005

Athens - The Greek agriculture minister recently announced that the country will destroy over 9,000 acres of fields planted with biotech-mixed cotton. The Greek government will pay affected farmers an estimated Euro4 million....

Cyprus/Greece/MaltaCyprusGreeceMalta

05.02.2005

Heraklion/Paris - Together with French Vaxon-Biotech S.A. the Herak-lion University Hospital in Crete has completed the phase I trial of Vaxon's candidate vaccine VX-001, which contains a single optimized cryptic peptide that...

Cyprus/Greece/MaltaCyprusGreeceMalta

13.11.2004

Athens - The Hellenic Innovation Centre presented a new technology in October that enables the production of high-grade pharmaceutical raw material like Inter-feron- and - , Erythropoietin, FSH, and HGH, without unwanted...

Cyprus/Greece/MaltaCyprusGreeceMalta

09.10.2004

Heraklion - The recent research advances on lymphocytes, the most sophisticated of all mature hematopoietic cell types, will be presented during the 2nd Gene Regulation in Lymphocyte Develop-ment Workshop to be held on October...

Cyprus/Greece/MaltaCyprusGreeceMalta

08.05.2004

Valetta - Further to the launch of its DNA Forensics division in February 2004, Synergene Profiling, a subsidiary of the Synergene Biotechnology Group, has successfully completed its first DNA forensic cases.Contracted on behalf...

Cyprus/Greece/MaltaCyprusGreeceMalta

08.05.2004

Athens - The Helenic Society for the Study and Applications of Growth Hormones will hold the 2nd International Congress on Adult Consequences of Childhood Endocrine Diseases from May 6-8 in Athens. Main topics are going to be the...

Cyprus/Greece/MaltaCyprusGreeceMalta

09.04.2004

Attard - The international network Gendia has recently developed a new fast pre-natal test for the most common aneuploidies by quantitative fluorescent PCR (QF-PCR). Gendia was founded last year by the Malta-based biotech company...

Cyprus/Greece/MaltaCyprusGreeceMalta

05.03.2004

Rhodos - SEED ECOLOGY 2004, the first thematic, scientific conference devoted exclusively to seeds and the environment, will take place in Rhodos (April 25 to May 1). The scientific program will cover all aspects of seed eco-logy...

Cyprus/Greece/MaltaCyprusGreeceMalta

05.02.2004

Athens - Biovista recently announced he licensing of its Journal Research AnalystTM (JRA) market intelligence tool by Upstate, Chalottesville/USA, one of the leading suppliers of cell signaling reagents and kinase screening...

Displaying results 31 to 40 out of 47

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-cyprus-greece-malta/browse/3/article/research-reform.html

Events

All Events

Stock list

All quotes

TOP

  • THROMBOGENICS (B)9.69 EUR9.24%
  • NOVACYT (F)4.80 EUR9.09%
  • HYBRIGENICS (F)1.85 EUR7.56%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • THERAMETRICS (CH)0.08 CHF-11.11%

TOP

  • WILEX (D)3.15 EUR303.8%
  • SANTHERA (CH)68.90 CHF102.6%
  • ADDEX (CH)4.06 CHF82.1%

FLOP

  • MERCK KGAA (D)64.28 EUR-49.5%
  • HYBRIGENICS (F)1.85 EUR-29.4%
  • PROSENSA (NL)9.24 USD-24.4%

TOP

  • SANTHERA (CH)68.90 CHF3433.3%
  • GW PHARMACEUTICALS (UK)422.75 GBP769.5%
  • PAION (D)2.80 EUR311.8%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-92.1%
  • THROMBOGENICS (B)9.69 EUR-69.2%

No liability assumed, Date: 23.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products